On May 15, 2026, Nurix Therapeutics, Inc. held its Annual Meeting, where shareholders approved the election of three directors, ratified PricewaterhouseCoopers LLP as auditors, and approved executive compensation. A total of 83,747,013 shares were represented, marking an 80.98% voting power presence.